Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

GHRP-6

Growth Hormone Releasing Peptide-6

Animal replicated

Research chemicalGHRP Growth Hormone Secretagogue Ghrelin Receptor Agonist Peptide

RouteInjectableGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: Growth Hormone Releasing Peptide-6 — Synthetic Hexapeptide — GHS-R1a Agonist — WADA S2 — GHRP, Growth Hormone Secretagogue, Ghrelin Receptor Agonist, Peptide.
Why people use it: Used primarily for muscle and performance and gut health.
What the evidence supports: The hunger is not a side effect. It is a direct pharmacological action at GHS-R1a hypothalamic appetite circuits. Understanding it prevents surprises and allows protocol design that uses it appropriately.

If you only read one thing

GHRP-6 is the prototype that all subsequent GHRPs improved upon. GHRP-2 was designed to produce more GH with less cortisol and prolactin. Hexarelin was designed for maximum GH potency. Ipamorelin was designed for clean GH release without any cortisol, prolactin, or ACTH elevation. Every refinement step moved away from GHRP-6's profile. And yet GHRP-6 remains in active community use — not despite its problems, but in some cases because of them. The hunger that arrives 20-30 minutes after a GHRP-6 injection is the strongest appetite stimulus any GHRP produces. For a hardgainer struggling to eat enough during a mass phase, this 'side effect' is the feature. GHRP-6 is the unrefined original that knows its place in the protocol architecture.

Check interactions →

Evidence reality check

Evidence snapshot

The hunger is not a side effect. It is a direct pharmacological action at GHS-R1a hypothalamic appetite circuits. Understanding it prevents surprises and allows protocol design that uses it appropriately.

From the chapter quick-reference block.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Muscle & Performance Gut & Digestive

Properties

Active malignancy: cautionWADA S2HPTA: stimulatingNot injectable

Half-life

Results: distribution half-life (t½α) = 7.6 ± 1.9 minutes

Evidence

CAnimal replicated

The Reverse Pharmacology Story

GHRP-6 was discovered in 1984 by studying chemical modifications of enkephalin amides. The compound that activated what seemed like a novel receptor was characterized pharmacologically for 12 years before that receptor was identified (GHS-R cloned in 1996, Howard et al.). Ghrelin itself — the endogenous ligand for GHRP-6's receptor — was not discovered until 1999 (Kojima et al., Nature). GHRP-6 predated its own receptor's discovery by 12 years and its natural endogenous ligand by 15 years. This is textbook reverse pharmacology: synthetic before natural.

The Hunger Effect

The most distinctive characteristic of GHRP-6 versus all subsequent GHRPs: profound appetite stimulation beginning 20-30 minutes post-injection and lasting 1-3 hours. This is GHS-R1a activation in the arcuate nucleus of the hypothalamus driving orexigenic (appetite-stimulating) signaling. The effect is stronger with GHRP-6 than GHRP-2 and dramatically stronger than ipamorelin. Community consensus: GHRP-6 is the preferred GHRP for bulking protocols where caloric intake is the primary limiting factor. It is the least preferred for cutting or body recomposition where appetite control matters.

Cortisol and Prolactin

GHRP-6 elevates cortisol and prolactin at standard doses (100-300 mcg SubQ). The mechanism: GHS-R1a activation stimulates the HPA axis (corticotropin-releasing hormone → ACTH → cortisol) and directly stimulates pituitary lactotrophs. Magnitude: cortisol elevation is moderate and transient (returning to baseline within 2-4 hours); prolactin elevation is similarly transient. Clinically meaningful? For most community users at standard doses and cycle lengths, the cortisol elevation is unlikely to produce significant catabolic consequences. For individuals sensitive to cortisol (high stress baseline, existing adrenal conditions) or prolactin (gynecomastia concern), ipamorelin is the better choice.

GHRP Class Position

GH potency: Hexarelin > GHRP-2 > GHRP-6 > Ipamorelin. Cortisol/Prolactin: GHRP-2 ≈ GHRP-6 > Ipamorelin ≈ 0. Appetite: GHRP-6 >> GHRP-2 > Ipamorelin. Selectivity: Ipamorelin > GHRP-2 > GHRP-6. GHRP-6 is the least selective major GHRP and produces the strongest hunger. It is the prototype, not the refined product. Use it when hunger is an asset; avoid it when it is not.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

AOD-9604

Same class · Peptide

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

Cagrilintide

Same class · Peptide

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

CIT Stack

Same class · GHRP

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.